Candid Therapeutics secures $370M to advance pioneering autoimmune therapies with repositioned T-cell engagers

San Diego, CA, September 9, 2024 (Business Wire) -- Candid Therapeutics has raised $370 million to advance novel therapies for autoimmune diseases, repurposing two T-cell engager antibodies. These antibodies, originally tested in oncology, are now being positioned to target B lymphocyte populations implicated in autoimmune conditions. The company, supported by a successful management team and top-tier investors, aims to lead in transformative autoimmune treatment development.

Read full article here.